Molecular markers associated with prostate cáncer: 3-nitrotyrosine and genetic and proteic expression of Mn-Superoxide dismutasa (Mn-SOD);Marcadores moleculares relacionados con cáncer de próstata: 3-nitrotirosina y expresión génica y proteica de la mn-superóxido dismutasa (mn-sod).

Archivos Espanoles de Urologia

Volumn 62, Issue 9, 2009, Pages 702-711

  Floriono Sánchez, Esoú ^a   Melchor, Castro Marín ^b   Noemí, Cárdenos Rodríguez ^c  

^a Laboratorio de Adiestramiento e Investigación Quirúrgica   (Mexico)

^b HOSPITAL CENTRAL MILITAR   (Mexico)

^c INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

Author keywords

3 nitrotyrosine; Benign prostatic hyperplasia; Mn SOD; Prostate cancer; Prostate specific antigen; Reactive oxygen species

Indexed keywords

3 NITROTYROSINE; 3-NITROTYROSINE; DRUG DERIVATIVE; SUPEROXIDE DISMUTASE; TYROSINE;

ARTICLE; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; HUMAN; MALE; METABOLISM; PROSTATE TUMOR;

GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; MALE; PROSTATIC NEOPLASMS; SUPEROXIDE DISMUTASE; TYROSINE;

EID: 75949093548     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. De Torres Ramírez I. Late pathology advances in the diagnosis and prognosis of prostate cancer. Arch. Esp. Urol. 2006; 59:1089-1110
2. Ahmed MM, Lee CT, Oesterling JE. Current trend in the epidemiology of prostatic disease: benign hyperplasia and adenocarcinoma. Boca Raton, Florid. CRC Press, 1997.
3. Instituto Nacional de Cancerología, Manual de Oncología, Editorial McGraw-Hill, 2003.
4. De Marzo AM, Nelson WG, Meeker AK, et al. Stem cell features of benign and malignant prostate aepithelial cells. J. Urol. 1998; 160:2381-2392
5. Ballesteros Sampol JJ. Ageing, diet, and prostatic cancer. Arch. Esp. Urol. 2002; 55:225-232
6. López Laur JD, Abud M, López Fontana C, Silva J, Cisella Y, Pérez Elizalde R, et al. Antioxidant power and cellular damage in prostate cancer. Arch. Esp. Urol. 2008; 61:563-569
7. Oberley TD. Oxidative Damage and Cancer. AJP. 2002; 160:403-408
8. Kahlos K, Anttila S, Asikainen T, et al. Manganese superoxide dismutase in healthy human pleural mesothelium and in malignant pleural mesothelioma. Am. J. Respir. Cell Mol. Biol. 1998; 18:570-580
9. Church SL, Grant JW, Ridnour LA, et al. Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc. Natl. Acad. Sci. 1993; 90:3113-3117
10. Izutani R, Asano S, Imano M, et al. Expression of manganese superoxide dismutase in esophageal and gastric cancers. J. Gastroenterol. 1998; 33:816-822
11. Nakata T, Suzuki K, Fujii J, et al. High expression of manganese superoxide dismutase in 7,12 dimet hylbenz[a]anthracene-induced ovarian cancer and increased serum levels in the tumor-bearing rats. Carcinogenesis, 1992; 13:1941-1943
12. Bostwick DG, Alexander EE, Singh R, et al. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer, 2000; 89:123-134
13. Gonzalo ML, Isaacs WB. Molecular pathways to prostate cancer. J. Urol. 2003; 170:2444-2446
14. Catalona W, Partin A, Slawin K, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279:1542-1547
15. Van Lersel MP, Witjes WP, De la Rosette JJ, et al. Prostate specific antigen density: correlation with histological diagnosis of prostate cancer, benign prostatic hyperplasia and prostatitis. Br. J. Urol. 1995; 76:47-53.
16. Yang QF, Sakurai T, Shan L, et al. Novel polymorphisms of prostate-specific antigen (PSA) gene associated with PSA mRNA expression in breast cancer. Journal of human genetic, 2000; 45:363-366
17. Torrijos FS, Alcina EL, Escudero JU, Deltoro MF, García AM, Romaguera AR, et al. Fast test serum PSA determination (Sd Bioline PSA). Arch. Esp. Urol. 2008;61:685-690
18. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med. 2004; 350:2239-2246
19. Hu Y, Rosen DG, Zhou Y, et al. Mitochondrial manganese-superoxide dismutase expression in ovarian cancer role in cell proliferation and response to oxidative stress. The J. Biol. Chem. 2005; 280:39485-39492
20. Masri FA, Comhair SA, Koeck T, et al. Abnormalities in nitric oxide and its derivatives in lung cancer. Am. J. Resp. Crit. Care Med. 2005; 172:597-605
21. Klotz T, Bloch W, Volberg C, et al. Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer. 1998; 82:1897-1903.
22. Marangoni K, Neves AF, Cardoso AM, et al. The endothelial nitric oxide synthase Glu-298-Asp polymorphism and its mRNA expression in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia. Cancer Detect Prev. 2006;30:7-13.
23. Baltaci S, Orhan D, Gögüs C, et al. Inducible nitric oxide synthase expression in benign prostatic hyperplasia, low and high grade prostatic intraepithelial neoplasia and prostatic carcinoma. BJU Int. 2001;88:100-103